Author Title [ Type(Desc)] Year
Filters: Author is Rosti, Vittorio  [Clear All Filters]
Journal Article
Mantelli M, Avanzini MAntonia, Rosti V, Ingo DM, Conforti A, Novara F, Arrigo G, Boni M, Zappatore R, Lenta E, et al. Comprehensive characterization of mesenchymal stromal cells from patients with Fanconi anaemia. Br J Haematol. 2015.
Abbà C, Campanelli R, Catarsi P, Villani L, Abbonante V, Sesta MAntonietta, Barosi G, Rosti V, Massa M. Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity. PLoS One. 2019;14(8):e0220189.
Balducci V, Faris P, Balbi C, Costa A, Negri S, Rosti V, Bollini S, Moccia F. The human amniotic fluid stem cell secretome triggers intracellular Ca oscillations, NF-κB nuclear translocation and tube formation in human endothelial colony-forming cells. J Cell Mol Med. 2021.
Rosti V, Campanelli R, Massa M, Viarengo G, Villani L, Poletto V, Bonetti E, Catarsi P, Magrini U, Grolla AA, et al. Increased plasma nicotinamide phosphoribosyltransferase (NAMPT) is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis. Am J Hematol. 2016.
Di Buduo CAndrea, Giannini S, Abbonante V, Rosti V, Hoffmeister K, Balduini A. Increased β4GALT1 expression associates with platelet surface galactosylation and thrombopoietin plasma levels in MPNs. Blood. 2020.
Salati S, Zini R, Nuzzo S, Guglielmelli P, Pennucci V, Prudente Z, Ruberti S, Rontauroli S, Norfo R, Bianchi E, et al. Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in Primary Myelofibrosis. Int J Cancer. 2015.
Norfo R, Zini R, Pennucci V, Bianchi E, Salati S, Guglielmelli P, Bogani C, Fanelli T, Mannarelli C, Rosti V, et al. miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells unveils the role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood. 2014.
De Cicco M, Lagreca I, Basso S, Barozzi P, Muscianisi S, Bianco A, Riva G, Di Vincenzo S, Pulvirenti C, Sapuppo D, et al. Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1) for the Treatment of NPM1-Acute Myeloid Leukemia. Cancers (Basel). 2023;15(10).